Edward J. Dulac III
Known title: Chief Financial OfficerCIK: 0001821530
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Fate Therapeutics Secures $15M CIRM Grant for Lupus Trial. Fate Therapeutics announced it received a $15 million grant from the California Institute for Regenerative Medicine to advance its Phase 2 RECLAIM-LN trial for lupus nephritis. This funding supports the development of the company's FT819 therapy. The news coincides with the stock trading near its 52-week low, providing a potential catalyst for the healthcare sector.
Transaction History
| NTLA | ▼ Sell | Open Market | 8,111 | $91K | 7/22/2026 | View on chart |
| NTLA | ▼ Sell | Open Market | 4,677 | $84K | 7/2/2026 | View on chart |
| NTLA | ▲ Buy | Grant | 61,280 | $0 | 3/1/2026 | View on chart |
| NTLA | ▼ Sell | Open Market | 6,379 | $59K | 1/5/2026 | View on chart |
| NTLA | ▼ Sell | Open Market | 7,462 | $105K | 7/23/2025 | View on chart |
| NTLA | ▲ Buy | Grant | 47,200 | $0 | 3/1/2025 | View on chart |
| NTLA | ▲ Buy | Grant | 66,324 | $0 | 7/22/2024 | View on chart |
| FATE | ▼ Sell | Open Market | 2,447 | $19K | 3/4/2024 | View on chart |
| FATE | ▼ Sell | Open Market | 1,849 | $9K | 1/29/2024 | View on chart |
| FATE | ▼ Sell | Open Market | 7,028 | $31K | 1/9/2024 | View on chart |
| FATE | ▼ Sell | Open Market | 5,182 | $19K | 1/2/2024 | View on chart |
| FATE | ▼ Sell | Open Market | 1,585 | $6K | 12/18/2023 | View on chart |
| FATE | ▼ Sell | Open Market | 4,718 | $13K | 8/18/2023 | View on chart |
| FATE | ▼ Sell | Open Market | 5,182 | $25K | 7/5/2023 | View on chart |
| FATE | ▼ Sell | Open Market | 7,331 | $38K | 1/10/2023 | View on chart |
| FATE | ▼ Sell | Open Market | 4,703 | $140K | 8/18/2022 | View on chart |
| FATE | ▼ Sell | Open Market | 432 | $13K | 8/18/2022 | View on chart |
| FATE | ▲ Buy | Grant | 33,302 | $0 | 1/25/2022 | View on chart |
| FATE | ▼ Sell | Open Market | 1,380 | $67K | 1/11/2022 | View on chart |
| FATE | ▼ Sell | Open Market | 390 | $19K | 1/11/2022 | View on chart |
| FATE | ▲ Buy | Option Exercise | 14,437 | $513K | 12/20/2021 | View on chart |
| FATE | ▼ Sell | Open Market | 15,977 | $959K | 12/20/2021 | View on chart |
| FATE | ▲ Buy | Grant | 59,540 | $0 | 11/19/2021 | View on chart |
| FATE | ▲ Buy | Option Exercise | 17,325 | $615K | 9/28/2021 | View on chart |
| FATE | ▼ Sell | Open Market | 19,460 | $1.2M | 9/28/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Intellia Therapeutics Appoints New Chief Medical Officer
Intellia Therapeutics announced the appointment of Jing L. Marantz as its new Chief Medical Officer. This leadership change occurred as the stock recently rose 7.6%, moving away from recent support levels. The news highlights a strategic shift in the company's medical leadership during a period of increased market activity.
Intellia Therapeutics Appoints New Chief Medical Officer. Intellia Therapeutics announced the appointment of Jing L. Marantz as its new Chief Medical Officer. This leadership change occurred as the stock recently rose 7.6%, moving away from recent support levels. The news highlights a strategic shift in the company's medical leadership during a period of increased market activity.